Endocrinol Metab > Volume 36(2); 2021 > Article |
|
Variable | Total (n=466) | Unilateral lesion (n=372) | Bilateral normal (n=55) | Bilateral lesion (n=39) | P value |
---|---|---|---|---|---|
Age, yr | 51.0 (43.0-59.0) | 51.0 (43.5-59.0) | 47.0 (36.0-60.5) | 58.0 (51.0-64.0)b,c | 0.003 |
Female sex | 231 (49.6) | 189 (50.8) | 28 (50.9) | 14 (35.9) | 0.204 |
Height, cm | 163.7 (157.6-170.0) | 163.3 (157.4-169.8) | 163.3 (156.2-170.9) | 167.6 (160.2-172.4) | 0.145 |
Weight, kg | 67.4 (57.9-76.5) | 67.1 (57.3-76.1) | 66.0 (57.2-75.8) | 71.5 (64.5-80.1) | 0.077 |
BMI, kg/m2 | 25.2 (22.7-27.3) | 25.2 (22.6-27.2) | 24.6 (22.3-26.7) | 25.9 (24.1-28.0) | 0.122 |
Systolic BP, mm Hg | 142.0 (131.0-156.0) | 142.0 (132.0-155.0) | 150.0 (131.5-160.0) | 135.0 (125.5-153.5) | 0.082 |
Diastolic BP, mm Hg | 90.0 (81.0-98.0) | 90.0 (81.0-97.0) | 91.0 (81.0-100.0) | 87.0 (77.5-97.0) | 0.262 |
Antihypertensive drug, DDD | 2.0 (1.0-3.4) | 2.0 (1.0-3.5) | 1.0 (0.0-2.7)a | 2.0 (1.0-3.5) | 0.039 |
eGFR, mL/min/1.73 m2 | 88.3 (75.2-104.5) | 88.0 (75.8-103.5) | 90.1 (74.8-107.3) | 84.7 (73.5-110.2) | 0.838 |
Serum potassium, mEq/L | 3.4 (3.0-4.0) | 3.3 (2.9-3.9) | 3.9 (3.5-4.2)a | 3.6 (3.0; 4.2) | <0.001 |
Hypokalemia | 228 (51.1) | 207 (55.6) | 12 (21.8)a | 19 (48.7)c | <0.001 |
PAC, ng/dL | 30.5 (23.4-45.2) | 31.3 (24.1-47.2) | 26.3 (19.7-34.0)a | 28.9 (21.9;41.9) | 0.001 |
PRA, ng/mL/hr | 0.2 (0.1-0.4) | 0.2 (0.1-0.4) | 0.2 (0.1-0.5) | 0.2 (0.2-0.3) | 0.321 |
ARR, ng/dL per ng/mL/hr | 146.5 (75.3-300.0) | 163.0 (76.2-320.5) | 96.0 (57.9-192.6)a | 130.0 (91.0-239.2) | 0.012 |
Nodule size on CT, cm | 1.5 (1.1-1.8) | 1.5 (1.1-1.8) | NA | 1.5 (1.1-1.8) | 0.182 |
Variable | Age, yr (<35, 35-39, 40-49, ≥50) | Age, yr (<50, ≥50) | ||||||
---|---|---|---|---|---|---|---|---|
|
|
|||||||
<35 (n=13) | 35-39 (n=20) | 40-49 (n=66) | ≥50 (n=99) | P value | <50 (n=99) | ≥50 (n=99) | P value | |
Age, yr | 33.0 (31.0-33.0) | 38.0a (36.5-39.0) | 45.0 (43.0-47.0) | 58.0b (53.0-63.0) | <0.001 | 43.0 (38.0-46.0) | 58.0 (53.0-63.0) | <0.001 |
|
||||||||
Female sex | 10 (76.9) | 8 (40.0) | 33 (50.0) | 52 (52.5) | 0.212 | 51 (51.5) | 52 (52.5) | >0.999 |
|
||||||||
Height, cm | 166.7 (163.0-169.0) | 168.1 (164.0-172.9) | 165.2 (159.6-172.0) | 161.0 (154.3-165.5) | <0.001 | 166.7 (161.0-171.1) | 161.0 (154.3-165.5) | <0.001 |
|
||||||||
Weight, kg | 58.0 (53.4-65.4) | 68.5a (58.5-77.3) | 66.2 (57.6-74.8) | 65.3 (56.3-73.1) | 0.152 | 66.0 (57.5-74.8) | 65.3 (56.3-73.1) | 0.294 |
|
||||||||
BMI, kg/m2 | 21.2 (19.7-25.9) | 23.6 (22.3-27.5) | 24.5 (21.9-25.8) | 24.5 (22.7-26.8) | 0.129 | 24.0 (21.7-26.1) | 24.5 (22.7-26.8) | 0.191 |
|
||||||||
Systolic BP, mm Hg | 142.0 (123.0-146.0) | 150.0 (131.0-162.5) | 146.0 (139.0-160.0) | 140.0 (130.5-155.0) | 0.055 | 145.0 (137.5-160.0) | 140.0 (130.5-155.0) | 0.033 |
|
||||||||
Diastolic BP, mm Hg | 93.0 (84.0-108.0) | 98.0 (82.5-109.5) | 95.5 (90.0-101.0) | 89.0 (80.0-95.0) | <0.001 | 95.0 (89.0-104.5) | 89.0 (80.0-95.0) | <0.001 |
|
||||||||
Anti-hypertensive drugs, DDD | 1.0 (0.0-3.0) | 2.0 (1.2-3.1) | 2.3 (1.0-3.5) | 3.0 (1.7-4.0) | 0.043 | 2.0 (1.0-3.3) | 3.0 (1.7-4.0) | 0.009 |
|
||||||||
eGFR, mL/min/1.73 m2 | 94.4 (90.1-103.2) | 93.0 (76.5-116.0) | 91.4 (77.5-110.2) | 81.5 (66.1-95.4) | 0.005 | 92.4 (77.7-111.2) | 81.5 (66.1-95.4) | <0.001 |
|
||||||||
Serum potassium, mEq/L | 2.8 (2.6-3.0) | 3.1a (2.8-3.3) | 2.9 (2.7-3.1) | 3.0 (2.7-3.2) | 0.074 | 2.9 (2.7-3.1) | 3.0 (2.7-3.2) | 0.465 |
|
||||||||
PAC, ng/dL | 51.2 (40.5-76.4) | 48.1 (23.6-58.5) | 46.8 (31.4-69.9) | 37.5 (28.1-48.8) | 0.009 | 48.5 (30.5-68.0) | 37.5 (28.1-48.8) | 0.003 |
|
||||||||
PRA, ng/mL/hr | 0.3 (0.1-0.3) | 0.1 (0.1-0.3) | 0.2 (0.1-0.3) | 0.1 (0.1-0.2) | 0.305 | 0.2 (0.1-0.3) | 0.1 (0.1-0.2) | 0.153 |
|
||||||||
ARR, ng/dL per ng/mL/hr | 238.8 (135.0-447.5) | 272.5 (99.2-576.0) | 268.5 (129.2-519.0) | 236.0 (141.3-395.5) | 0.736 | 267.0 (126.7-515.5) | 236.0 (141.3-395.5) | 0.261 |
|
||||||||
Nodule size on CT, cm | 1.5 (1.3-1.6) | 1.5 (1.0-2.0) | 1.8 (1.4-2.3) | 1.5b (1.1-1.8) | 0..001 | 1.6 (1.3-2.0) | 1.5 (1.1-1.8) | 0.001 |
PA, primary aldosteronism; PAC, plasma aldosterone concentration; CT, computed tomography; BMI, body mass index; BP, blood pressure; DDD, defined daily dose; eGFR, estimated glomerular filtration rate; PRA, plasma renin activity; ARR, aldosterone-to-renin ratio.
Seung Hun Lee
https://orcid.org/0000-0003-0496-247X
Jung Hee Kim
https://orcid.org/0000-0003-1932-0234